ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
T-cell Childhood Acute Lymphoblastic Leukemia
Children's Oncology Groupprotein_peptidePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the T-cell Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHOTREXATE National Cancer Institute (NCI) | Phase 3 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
Calcium folinate pentahydrate National Cancer Institute (NCI) | Phase 3 | BB |
ETOPOSIDE National Cancer Institute (NCI) | Phase 3 | BB |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 3 | BB |
View all 28 →
Same molecule, other indications
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →